APA (7th ed.) Citation

Kim, D. W., & Saußele, S. (2018). Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: The DASPERSE study. Annals of hematology, 97(8), . https://doi.org/10.1007/s00277-018-3295-8

Chicago Style (17th ed.) Citation

Kim, Dong Wook, and Susanne Saußele. "Outcomes of Switching to Dasatinib After Imatinib-related Low-grade Adverse Events in Patients with Chronic Myeloid Leukemia in Chronic Phase: The DASPERSE Study." Annals of Hematology 97, no. 8 (2018). https://doi.org/10.1007/s00277-018-3295-8.

MLA (9th ed.) Citation

Kim, Dong Wook, and Susanne Saußele. "Outcomes of Switching to Dasatinib After Imatinib-related Low-grade Adverse Events in Patients with Chronic Myeloid Leukemia in Chronic Phase: The DASPERSE Study." Annals of Hematology, vol. 97, no. 8, 2018, https://doi.org/10.1007/s00277-018-3295-8.